Dossier
most-favored nation
Coverage of most-favored nation in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
A Medicare pilot program called GUARD, aimed at lowering drug prices through 'most-favored nation' pricing, could lose significant savings if rare disease drugs are excluded, according to biotech lobbying efforts. Additionally, reports of potential mergers between AstraZeneca and Bristol Myers Squibb have been denied by anonymous sources.
- STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
Biotech companies are lobbying the Trump administration to exclude rare disease treatments from Medicare price-lowering pilots. The Rare Disease Company Coalition met with the White House Office of Management and Budget to discuss exemptions from Trump’s plan to align U.S. drug prices with those in other countries through a most-favored nation policy.